1 Metabolomic Alterations in Crimean Congo Hemorrhagic Fever

2 Explored Through a Nationwide Study Using NMR Spectroscopy

- 3 Oktay Göcenler^{1,#}, Kerem Kahraman^{1,#}, Derya Yapar^{2,3}, Yaren Kahraman¹, Cengizhan
- 4 Büyükdağ¹, Gülen Esken⁴, Serena Ozabrahamyan⁵, Tayfun Barlas⁴, Yüksel Karadağ³, Aysel
- 5 Kocagül Çelikbaş^{2,3}, Füsun Can^{4,6}, Nurcan Baykam^{2,3}, Mert Kuşkucu^{4,7}, Önder Ergönül^{4,7},
- 6 *Çağdaş Dağ^{1, 4,}**
- 7 ¹Nanofabrication and Nanocharacterization Center for Scientific and Technological Advanced
- 8 Research (n²STAR), Koç University, İstanbul, Türkiye
- 9 ²Hitit University, School of Medicine, Çorum, Türkiye
- ³Department of Infectious Diseases and Clinical Microbiology, Çorum Erol Olçok Training and
- 11 Research Hospital, Çorum, Türkiye
- ⁴Koç University Isbank Center for Infectious Diseases (KUISCID), Koc University, Istanbul,
- 13 Türkiye
- 14 ⁵The Ohio State University Wexner Medical Center, Columbus, USA
- ⁶Koç University School of Medicine, Department of Medical Microbiology, Istanbul, Türkiye
- ⁷Koç University School of Medicine, Department of Clinical Microbiology and Infectious
 Diseases, Istanbul, Türkiye

17 Diseases, Istar18

- 19 *Corresponding author: <u>cdag@ku.edu.tr</u>
- 20 [#]equal contribution
- 21
- 22

23 SUMMARY

Crimean-Congo Hemorrhagic Fever (CCHF) is a severe tick-borne viral disease with high 24 25 mortality rates and significant public health implications. Despite its global prevalence, the 26 mechanisms underlying its pathogenesis remain poorly understood, and effective diagnostic and 27 therapeutic tools are limited. Metabolomics, as a powerful tool for exploring host-pathogen 28 interactions, offers a promising avenue for identifying biomarkers and elucidating disease 29 mechanisms. In this study, we investigated the metabolic alterations in CCHF patients using non-30 targeted metabolomics to enhance understanding of disease pathogenesis, improve diagnostic 31 capabilities, and identify potential therapeutic targets. A nationwide analysis was conducted on 32 the blood serum of 29 CCHF patients and 10 healthy controls, employing Nuclear Magnetic 33 Resonance (NMR) spectroscopy. Serum samples were collected over four consecutive days, and 34 metabolic profiling was performed using Partial Least Squares Discriminant Analysis (PLS-DA) 35 and Variable Importance in Projection (VIP) scoring to identify key metabolic pathways and 36 compounds. Significant disruptions in metabolic pathways were observed in CCHF patients, 37 particularly in purine and pyrimidine metabolism, the TCA cycle, and redox-related processes. 38 Elevated levels of metabolites such as S-adenosyl homocysteine (SAH), guanosine triphosphate 39 (GTP), inosine monophosphate (IMP), adenosine monophosphate (AMP), carnosine, 2'deoxyuridine, nicotinamide adenine dinucleotide phosphate (NADP+), and maleate were 40 41 identified. These metabolites demonstrated potential as biomarkers for disease severity and 42 progression, with distinct metabolic profiles observed between moderate and severe cases. This 43 study provides the first comprehensive metabolomic analysis of CCHF, highlighting critical 44 metabolic pathways disrupted during infection. The findings underscore the utility of NMR-45 based metabolomics for identifying biomarkers that facilitate early diagnosis, prognosis, and

therapeutic development. These results pave the way for future research to validate the identified
biomarkers and explore targeted treatment strategies to improve patient outcomes in this severe
viral infection.

49 **1. Introduction**

50 Crimean-Congo Hemorrhagic Fever (CCHF) is a severe viral infection with substantial 51 implications for public health in a wide range of countries in Asia, Africa, Southern Europe and 52 the Middle East. CCHF is caused by CCHF virus (CCHFV) belonging to the genus of 53 Orthonairovirus, and the family of Nairoviridae being one of deadliest viruses of its kind with 54 reported mortality rate of 3-30% (1). CCHFV is transmitted to humans through tick bites of infected ticks, contact with blood or tissues of infected livestock, or contact with infected 55 56 patients (2). The exact course of pathogenesis of CCHF is not clearly known however it is 57 divided into four phases: incubation, pre-haemorrhagic, haemorrhagic and convalescence [2]. 58 CCHF is classified as a severe hemorrhagic fever with a short incubation period of 1-3 days 59 although longer incubation periods have been documented [3]. The onset of infection is often 60 sudden and includes symptoms, fever, diarrhea, vomiting, nausea, myalgia, back and abdominal pain followed by an hemorrhagic phase where severe bruises, uncontrollable bleeding at the 61 62 body orifices are observed and in severe cases, deterioration of kidneys, liver and lungs [4]. Deaths associated with the infection mostly occur between 5-14 days from the start of the 63 viremic phase [5]. In terms of treatment, early hospitalizations and early administration of 64 65 therapeutics are shown to reduce both severity and mortality of CCHF [6]. Hence, lack of early detection of CCHF is one of the leading factors causing the particular high mortality rate of 66 CCHF. 67

68 There are several challenges of diagnosing CCHF infection particularly before the hemorrhagic 69 phase of the infection and patients who are not suspected of being bitten by infected ticks or 70 contacted with infected livestock. CCHF is comparatively uncommon in specific regions, which 71 may lead healthcare providers to initially overlook it as a potential diagnosis. Likewise, there are 72 documented cases of difficulties diagnosing CCHF, both because of the latter but also the 73 absence of a universally applicable diagnostic kit for surveillance and diagnosis of all CCHFV 74 strains [7]. Standard blood tests such as hemogram, biochemical analysis and physical 75 examination at the beginning of hospitalization is applied on all patients who are suspected to be 76 infected with CCHF although the results are often relevant for short term prognostic factors as 77 biochemical values change often quickly. For more comprehensive and standard diagnostic 78 methods, viral antigen and nucleic acid amplification tests are employed [8]. The initial 79 symptoms of CCHF, such as fever, headache, and muscle aches, are rather non-specific hence 80 diagnosing CCHF early by differential diagnosis can be difficult [5]. However biomarkers, 81 essentially biomolecules, may provide a measure of specific diseases or their stages due to their 82 varying concentrations. Bio markers are instrumental in diagnosing and monitoring the 83 progression of viral infections. The associated changes in their levels, often indicative of the 84 disease, are typically attributed to the host's immune reaction and the disturbance of key 85 biochemical routes in reaction to the infectious process. In this sense, omics studies and biomarkers could be used for both analysis and diagnosis of CCHF and for characterizing better 86 87 treatment strategies of hospitalized patients swiftly is crucial to pinpoint optimal treatment 88 strategies for treating CCHF [9].

So far there is only one omics study which investigates host-viral response and pathogenesis of
CCHF utilizing transcriptomics and proteomics methods [10]. Led by this gap in the literature,

91 we conducted a nationwide analysis of metabolomes of patients hospitalized due to CCHF. 92 Turkey has over 10,000 cases of CCHF with an average fatality rate of 5%, making it a critical 93 public health concern affecting people living in rural areas as ticks are widespread in these 94 regions [11]. In our present investigation, we employed Nuclear Magnetic Resonance (NMR) spectroscopy exploratory metabolomics to investigate the overall temporal variations in plasma 95 96 metabolites during a seasonal outbreak of CCHF infection. We employed PLS-DA statistical 97 analysis of the blood serum metabolome of CCHF patients and categorized certain metabolomes linked to metabolic dysregulation caused by CCHF. Preliminary results from our study suggest 98 99 that specific metabolic markers can be identified in the serum of CCHF patients pointing to 100 metabolic dysregulation, which may allow for earlier diagnosis and more targeted treatment 101 strategies. Additionally, being the first study to categorize alterations of patient metabolome 102 during CCHF viremic phase may be valuable for efforts to develop therapeutics or targeted 103 treatment strategies to reduce the severity and high mortality rate of CCHF.

104 **2. Materials and methods**

105 Monitoring of CCHF diagnosed patients and collection of the samples from the patients: 106 Patients who were diagnosed with CCHF were selected from Corum Hitit University Hospital. 107 The first sample collection was conducted in April 2022, and blood samples were collected daily 108 using Ethylenediaminetetraacetic acid (EDTA) tubes. In current metabolomics studies, opinions 109 regarding the appropriate determination of sample size can considerably vary. However, 110 numerous statistical analyses have underscored that a substantial sample size, for achieving 111 meaningful results, around 30 samples [12]. In this study, serum specimens were procured from 112 29 patients (n=29) diagnosed with CCHFV infection, as well as from 10 healthy control group. 113 CCHF patients also admitted to the hospital with an infection diagnosis were subclassified into

114 two categories based on their blood test values and symptoms: moderate (n=24) and severe 115 (n=5). Four blood serum samples from patients each consecutive day (n=116 samples) and a 116 single sample from the control group (n=10 samples) was taken. These blood samples were then 117 subjected to centrifugation for 5 minutes at 3000g to separate the sample into plasma, white 118 blood cell, and red blood cell phases. The plasma phase was extracted and subjected to 119 metabolite extraction using multiple approaches: single methanol extraction, triple alcohol 120 extraction, Methanol-chloroform, Acetone, Acetonitrile, and Ultrafiltration. Cold methanol-121 chloroform was chosen as the most effective extraction and used for extraction of all samples. 122 Only the polar metabolites in the plasma were investigated, while proteins and apolar compounds 123 were removed from the plasma samples. Overall in this study, we utilized a rigorous approach to 124 sample collection, preparation, and analysis to investigate polar metabolites in the plasma of 125 CCHF patients [13].

Ethical Statement: The study was approved by Koç University Committee on Human Research (01.12.2021/ 2021.436.IRB2.079) and all the procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committee ethical standards. A written informed consent was obtained from all patients.

NMR sample preparation: 4 mL ice-cold methanol-chloroform (1:1) mixture was added to 2
mL serum for methanol-chloroform extraction. The mixture was vortexed for 30 seconds and
incubated for 10 minutes on ice. After incubation the mixture was centrifuged at 4500g at 4°C
for 30 minutes. The methanol phase was collected and dried using a vacuum concentrator. The
dried samples were dissolved in 550 uL D₂O based NMR sample solution (50 mM PBS (pH 7.4),
20mM NaCl, 1 mM DSS) for standardized sample preparation.

136 **NMR data collection, processing and statistical analysis:** 500 MHz Bruker Ascend magnet 137 with BBO paired resonance probe and Avance NEO console was used for NMR data collection. 138 1D NOESY-presat (noesygppr1d) pulse sequence was used for data collection. Each NMR data 139 spectrum is composed of 4K screening and 32K complex data points. Spectrum widths were set 140 to 9615.4 Hz. Bruker Topspin 4.2.0 software was used for NMR data processing. Data was 141 divided into 0.02 ppm data packages along with their normalization coefficients. The dataset, 142 which comprises data packets with a resolution of 0.02 ppm, was analyzed using the 143 MetaboAnalyst 5.0 online metabolomics statistical analysis software. Henceforth the data will 144 be referred to as (Bin.x.xx [ppm]) data packets and the day of when sample was taken. All data 145 points were normalized using the average centering normalization method. Following this 146 normalization, the dataset underwent statistical analysis using Partial Least Squares Discriminant 147 Analysis (PLS-DA). PLS-DA is a classification and discrimination technique based on the 148 Partial Least Squares (PLS) regression method. This method is widely utilized to determine the 149 differences between classes, particularly in high-dimensional and multivariate datasets. PLS-DA 150 is a commonly employed method in analyzing complex biological systems, such as 151 metabolomics studies. The VIP Projection variable importance score plot is a graph that is 152 utilized to assess the outcomes of PLS-DA and determine the most significant variables in the 153 analysis. VIP scores quantify the importance of each variable (e.g., metabolites) in classification 154 and aid in identifying the most critical features. VIP scores are computed based on the 155 contribution of each variable to the components (latent variables) in the PLS-DA model. The 156 values begin at 1, and higher VIP scores indicate that the variable is more important for 157 classification. Variables with VIP scores greater than 1 are generally deemed significant, 158 although this threshold may vary in practice. The VIP score plot displays the VIP scores of the

159 variables on the vertical axis, while the variables themselves or their indices are shown on the 160 horizontal axis. This graph facilitates the identification of important variables visually and helps 161 focus on the variables that require prioritization in the analysis. In the VIP score graph, the peaks 162 at the relevant ppm values that make up the data packages (Bin.x.xx) have been examined in 163 more detail and the metabolites to which they belong have been identified. For this operation, 164 NMR spectra have been reopened, and the metabolites to which the peak in the relevant ppm 165 region belongs have been determined using the Chenomx software. It is thought that some peaks 166 might belong to metabolites not found in the database, and the molecules these peaks belong to 167 have not been identified. Further investigation and characterization may be required to fully 168 understand these unidentified peaks and their role in the overall metabolic profile, ensuring that 169 the final analysis provides an accurate reflection of the biological system under investigation.

Metabolomic pathway visualization: All metabolic pathways visualized using Metastate software Version BETA (https://metastate.bio) (Metastate Bio Inc.). Metastate algorithm employs the Kyoto Encyclopedia of Genes and Genomes (KEGG) database as its foundational input source. Software systematically retrieves details pertaining to biological pathways, chemical compounds, and molecular reactions of interest. Software curates and assembles a dynamic graphical representation of the data.

176 **3. Results**

In this study, 29 patients diagnosed with Crimean-Congo Hemorrhagic Fever (CCHF) and 10 healthy individuals serving as control subjects were included. The control group had a mean age of 50.1 years (range: 40–64 years), while the CCHF patient group had a slightly higher mean age of 50.5 years, with a wider age range of 22–77 years. A total of 126 blood samples were 181 collected for analysis. Serum samples were prepared using methanol extraction, followed by 182 Nuclear Magnetic Resonance (NMR) spectroscopy. The metabolite profiles obtained were 183 subjected to comprehensive statistical analysis. This analysis incorporated data from all collected 184 samples over four consecutive days and categorized them into moderate, severe, and control 185 groups for comparative evaluation. Detailed procedures are described in the Materials and 186 Methods section.

Partial Least Squares Discriminant Analysis (PLS-DA) was employed to develop a model incorporating the primary components (latent variables) of the dataset. The model focused on the first five components, which were pivotal for data classification and accounted for most of the dataset's variance. The corresponding score plots, presented as two-dimensional graphs, illustrate the pairwise comparisons of these components (Figure 1a).

192 The PLS-DA score plot (Figure 1b) clearly differentiates between healthy and diseased 193 individuals. PLS-DA, well-suited for handling high-dimensional data, effectively identifies the 194 key variables responsible for distinguishing health states. This approach revealed a distinct 195 separation based on variations and correlations within the biomarker data. To further explore the 196 critical contributors to this separation, the Variable Importance in Projection (VIP) scores were 197 analyzed. The PLS-DA VIP score plot (Figure 1c) highlights the variables with the most 198 significant influence on the discrimination process, with the top 15 variables identified. VIP 199 scores provide insights into the relevance of each variable, aiding in the identification of 200 biomarkers that significantly differ between healthy and diseased states.

Figure 1c demonstrates that some data buckets exhibit lower concentration values (indicated in blue) in the control group, which progressively increase over time. Furthermore, the identified

203 compounds displayed a marked increase in concentration, as corroborated by enhanced signals204 from their respective data buckets (Figure 1d).

Statistical analysis was performed across three distinct groups, incorporating samples collected over four days from both patient groups. While patient samples were successfully distinguished from the control group, no significant differences were observed between the moderate and severe disease groups. Key metabolites found to be elevated in the patient groups compared to controls included SAH, GTP, carnosine, maleate, 2-deoxyuridine, IMP, AMP, and NADP+.

210 As a secondary approach to data analysis, metabolite profiles were evaluated using samples 211 collected on days 1 and 2 of hospitalization, representing the early stages of infection. Patients 212 were categorized into severe and moderate groups based on clinical severity, while blood 213 samples from healthy individuals were used as the control group for statistical comparisons 214 (Figure 2). This focused analysis aimed to investigate metabolite changes during the initial phase 215 of the disease. In addition to compounds identified in the initial analysis, novel metabolites with 216 significant increases on days 1 and 2 were detected, suggesting their potential involvement in the 217 pathogenesis of Crimean-Congo Hemorrhagic Fever (CCHF).

A comprehensive metabolomic analysis of blood serum from CCHF patients revealed distinct metabolite patterns corresponding to infection severity. Partial Least Squares Discriminant Analysis (PLS-DA) score plots and Variable Importance in Projection (VIP) scores (Figure 3) highlighted notable differences in metabolite profiles between severe and moderate cases. In severe CCHF infections, metabolites such as AMP, IMP, and NAAD were significantly elevated in the serum, whereas these compounds were less prominent in samples from patients with

moderate infection. Conversely, GTP was markedly increased in the moderate infection groupbut was not significantly detected in the severe group.

Overall, these findings highlight substantial metabolic differences between moderate and severe CCHF infections, pointing to critical pathways potentially involved in CCHF pathogenesis. These results underscore the importance of early-stage metabolite profiling to enhance our understanding of disease mechanisms and identify potential biomarkers for severity stratification.

231 **4. Discussion**

232

233 In this study, we present the first non-targeted metabolomics analysis of Crimean-Congo 234 Hemorrhagic Fever (CCHF) to enhance the understanding of its pathogenesis, improve diagnostic capabilities, and aid in the development of potential therapeutic interventions. Using 235 236 Nuclear Magnetic Resonance (NMR) spectroscopy, we identified significant increases in key 237 metabolites, including S-adenosyl homocysteine (SAH), guanosine triphosphate (GTP), 238 carnosine, maleate, 2'-deoxyuridine (2'-dU), inosine monophosphate (IMP), adenosine 239 monophosphate (AMP), and nicotinamide adenine dinucleotide phosphate (NADP+), in the 240 blood serum of CCHF patients. These findings suggest that these metabolites may play critical 241 roles in the pathogenesis of CCHF and serve as important biomarkers for early detection and 242 monitoring of disease progression.

243 Metabolomics has emerged as a powerful tool for studying host-pathogen interactions by 244 revealing metabolic alterations induced by viral infections. To date, only one prior omics study 245 utilizing mass spectrometry (MS) has investigated the interaction between the host and CCHF

virus (CCHFV). Both NMR and MS are widely used in metabolomics, with each method offering distinct advantages depending on the research objectives. NMR spectroscopy is particularly suitable for non-targeted metabolomics due to its superior reproducibility, minimal sample preparation, and ability to analyze complex biofluids. It also provides consistent spectra across different instruments and laboratories, making it highly reliable for diagnostic and prognostic studies. On the other hand, MS offers higher sensitivity and is often preferred for targeted metabolomics studies.

253 The utility of NMR metabolomics has been demonstrated in the analysis of host metabolic 254 changes induced by various viral infections, including HIV, dengue virus (DENV), and 255 chikungunya virus. Moreover, metabolomics approaches have been successfully applied to study 256 other viral hemorrhagic fevers, such as Ebola, Marburg, and dengue, yielding promising results 257 for early diagnosis and prognosis prediction. Similarly, our findings underscore the potential of 258 NMR metabolomics in elucidating the complex metabolic interactions between CCHFV and its 259 host. The observed metabolic changes in CCHF patients offer new insights into the mechanisms 260 of disease pathogenesis and highlight potential pathways for targeted therapeutic interventions.

By focusing on metabolite profiles in CCHF, this study demonstrates the value of NMR-based metabolomics in addressing the gaps in knowledge surrounding this severe disease. Our findings not only advance the understanding of CCHF pathogenesis but also provide a foundation for further research aimed at identifying effective biomarkers and therapeutic targets. These results emphasize the critical role of metabolomics in uncovering host-pathogen dynamics and improving clinical outcomes in viral infections.

267 Among the notable metabolites detected, S-adenosyl homocysteine (SAH) emerged as a 268 significant intermediate in the metabolic pathways of CCHF patients. SAH, a precursor to 269 homocysteine and adenosine, serves as the substrate for the enzyme SAH hydrolase, a critical 270 component of the S-adenosylmethionine (SAM/AdoMet) regeneration cycle (Figure 4a). 271 Elevated SAH levels were observed in CCHF patients early during hospitalization, underscoring 272 its potential relevance in the disease's pathogenesis. This observation aligns with findings from a 273 genomic study linking Methylenetetrahydrofolate reductase (MTHFR) polymorphisms to a 274 predisposition for milder forms of CCHF [18]. Since MTHFR plays a central role in folate 275 metabolism and methylation processes, these results suggest that disruptions in methylation 276 pathways during the viremic phase could serve as prognostic indicators for CCHF severity.

277 SAM is a key methyl donor in various cellular methylation reactions, including those involved in 278 5' RNA capping, a process critical for viral replication and transcription [19]. Evidence from 279 other viral families, such as flaviviruses [20], and Ebola, whose L protein exhibits 280 methyltransferase activity, indicates that methylation mechanisms can influence RNA cap 281 structure and internal adenosine-2'-O-methylation [21]. These parallels highlight the potential 282 importance of methylation pathways in CCHF pathogenesis. The additional complexity of RNA methylation in some viral families suggests that SAM-related domains within viral replication 283 284 complexes could represent promising therapeutic targets.

Our findings emphasize the need for further research into SAM-related pathways to unravel their implications for viral replication and host-pathogen interactions in CCHF. These pathways not only provide insight into disease mechanisms but also present opportunities for the development of targeted therapeutic interventions, particularly those aimed at disrupting key methylation processes critical for viral survival.

290 GTP, AMP, and inosine monophosphate (IMP) are key nucleotides involved in purine 291 metabolism, essential for energy production and nucleic acid synthesis (Figure 4b). Elevated 292 levels of GTP and IMP are well-documented indicators of viral infections, particularly among 293 viruses in the Orthornavirae kingdom. In the context of CCHF, the increase in these purine 294 metabolites aligns with the known mechanism of action of broad-spectrum antivirals like 295 Ribavirin. As a nucleotide analog, Ribavirin targets the substrate-binding site of the IMPDH 296 enzyme, thereby reducing RNA synthesis in infected cells by downregulating GTP synthesis 297 [22]. Monitoring these metabolites could provide valuable insights into the efficacy of antiviral 298 treatments. Additionally, quantifying shifts in GTP and IMP concentrations offers a potential 299 strategy to optimize therapeutic interventions in clinical trials, enhancing the effectiveness of 300 antiviral agents targeting purine metabolism [23].

301 Carnosine (β -alanyl-L-histidine) (Figure 4c), a dipeptide with antioxidant, anti-glycation, and 302 anti-inflammatory properties, was also significantly elevated in CCHF patients. Predominantly 303 found in skeletal muscle and the brain, increased carnosine levels may reflect a compensatory 304 response to oxidative stress, infection-induced cell death, or muscle mass reduction due to 305 hospitalization. Carnosine has demonstrated antiviral potential against Zika, dengue, and SARS-CoV-2, reducing viral replication and alleviating symptoms. While its therapeutic utility against 306 307 CCHF remains to be established, these findings highlight the need for further investigation into 308 its potential as a treatment option.

2'-Deoxyuridine (2'-dU), an intermediate in thymidylate synthesis (Figure 4d), also showed
significant elevation in CCHF patients. This metabolite, a precursor for DNA synthesis, plays a
role in antiviral therapies, such as Edoxudine, which target DNA viruses [24–26]. Variants of 2'dU, such as BVDU, have shown efficacy against Herpes simplex virus type 1 (HSV-1) and

varicella-zoster virus (VZV) [27]. While 2'-dU is typically associated with DNA virus activity,
its elevated levels in CCHF patients may suggest broader disruptions in pyrimidine metabolism,
potentially linked to the metabolic dysregulation observed in this study.

316 Nicotinamide adenine dinucleotide phosphate (NADP+) serves as a critical cofactor in enzymatic 317 reactions, primarily within the pentose phosphate pathway, where it supports fatty acid synthesis 318 and the regeneration of reduced glutathione. Its role in redox reactions also underscores its 319 importance in the antioxidant defense system. Elevated NADP+ levels in CCHF patients could 320 reflect increased metabolic activity related to energy production and nucleotide synthesis. This 321 hypothesis is further supported by the observed overlap in the elevations of NADP+, GTP, IMP, 322 and AMP, indicating a coordinated upregulation of energy metabolism pathways. The significant 323 increase in these metabolites in severe cases (Figure 3) underscores their potential relevance in 324 disease progression and severity.

Maleate (cis-butenedioic acid), a dicarboxylic acid and trans-isomer of fumaric acid, plays a role in nicotinate and nicotinamide metabolism [29]. Elevated maleate levels in CCHF patients suggest underlying metabolic disruptions. Previous studies have demonstrated that maleate can inhibit the tricarboxylic acid (TCA) cycle, lower ATP levels, and impair enzymatic activity, leading to systemic metabolic imbalances. These findings warrant further investigation into the potential implications of maleate in the pathophysiology of CCHF [30].

In summary, these metabolomic findings reveal significant disruptions in purine, pyrimidine, and
energy metabolism pathways in CCHF patients. Metabolites such as GTP, IMP, AMP, carnosine,
2'-dU, NADP+, and maleate provide valuable insights into the pathogenesis of the disease and
highlight potential biomarkers for disease progression and therapeutic targets.

335

336

337

338 Conclusion

339 In this study, we conducted a nationwide analysis of blood serum metabolites from patients 340 hospitalized due to Crimean-Congo Hemorrhagic Fever (CCHF), employing Nuclear Magnetic 341 Resonance (NMR) spectroscopy as a novel approach to investigate host-pathogen interactions 342 and the pathogenesis of CCHFV. Our findings revealed significant alterations in several key 343 metabolites, including S-adenosyl homocysteine (SAH), guanosine triphosphate (GTP), inosine 344 monophosphate (IMP), adenosine monophosphate (AMP), 2'-deoxyuridine (2'-dU), nicotinamide 345 adenine dinucleotide phosphate (NADP+), carnosine, and maleate. Notable changes were 346 observed in pathways related to the TCA cycle, nucleic acid synthesis, and redox-associated 347 coenzymes, highlighting the systemic metabolic impact of CCHFV infection.

The elevation of metabolites such as SAH underscores the potential impact of methylation processes on CCHF pathogenesis and prognosis, linking viral replication to host epigenetic regulation. Similarly, the observed disruptions in purine metabolism, particularly the increased levels of GTP and IMP, suggest potential therapeutic implications, as these pathways are targeted by antiviral agents like Ribavirin. The role of other metabolites, such as carnosine and maleate, indicates a systemic response to oxidative stress and cellular damage, providing further insight into the host's metabolic adaptation during infection.

Our findings align with prior metabolomics studies on other viral hemorrhagic fevers and highlight the utility of NMR-based metabolomics for uncovering biomarkers that may facilitate early diagnosis, prognosis prediction, and therapeutic development. The distinct metabolic profiles observed between moderate and severe CCHF cases further emphasize the relevance of these biomarkers in stratifying disease severity and monitoring treatment efficacy.

This study paves the way for future investigations to validate these biomarkers in larger cohorts and explore the therapeutic potential of targeting the identified pathways. By advancing the understanding of CCHF pathogenesis, our results contribute to the development of more effective diagnostic and therapeutic strategies, ultimately improving patient outcomes in this severe viral infection.

365 Author Contributions

Cağdaş Dağ: Conceptualization, Methodology, Supervision, Funding acquisition, Writing-366 367 Reviewing and Editing, Writing-Original draft preparation Kerem Kahraman: Investigation, 368 Formal analysis, Visualization, Writing-Reviewing and Editing Oktay Göcenler: Investigation, 369 Formal analysis, Writing-Original Draft, Visualization Derya Yapar: Investigation Yaren 370 Kahraman: Investigation, Formal analysis Cengizhan Büyükdağ: Formal analysis, Writing-371 Original Draft Gülen Esken: Methodology, Investigation Serena Ozabrahamyan: 372 Methodology, Investigation Tayfun Barlas: Investigation Yüksel Karadağ: Investigation Aysel 373 Kocagül Celikbas: Investigation Füsun Can: Supervision, Investigation Nurcan Baykam: 374 Supervision, Investigation Mert Kuskucu: Supervision, Writing-Reviewing and Editing Önder 375 **Ergönül:** Supervision, Funding acquisition, Conceptualization, Methodology

376 ACKNOWLEDGMENT

377 CD acknowledges support from TU BI TAK (Project No: 221S353). The authors

acknowledge the use of the services and facilities of n^2 STAR-Koç University Nanofabrication

and Nanocharacterization Center for Scientific and Technological Advanced Research. The

- authors gratefully acknowledge use of the services and facilities of the Koc University Is Bank
- 381 Infectious Disease Center (KUIS-CID). We are also immensely grateful to Fırat Kahya, Boran
- 382 Saruhan and Oğuzcan Ünver for constructive feedback and for their comments.

383 **References**

[1] Belhadi, D., Baied, M. E., Mulier, G., Malvy, D., Mentré, F., & Laouénan, C. (2022). The
number of cases, mortality and treatments of viral hemorrhagic fevers: A systematic review.
PLOS Neglected Tropical Diseases, 16(10), e0010889.
https://doi.org/10.1371/journal.pntd.0010889

[2] Hoogstraal H. (1979). The epidemiology of tick-borne Crimean-Congo hemorrhagic fever in
Asia, Europe, and Africa. *Journal of medical entomology*, *15*(4), 307–417.
https://doi.org/10.1093/jmedent/15.4.307

391 [3] Whitehouse, C. A. (2004). Crimean?Congo hemorrhagic fever. *Antiviral Research*, 64(3),
392 145–160. https://doi.org/10.1016/j.antiviral.2004.08.001

[4] Elaldi, N., Bodur, H., Ascioglu, S., Celikbas, A. K., Özkurt, Z., Vahaboglu, H.,
Leblebicioglu, H., Yilmaz, N., Engin, A., Şencan, M., Aydin, K., Dokmetas, I., Çevik, M. A.,
Dokuzoğuz, B., Tasyaran, M. A., Öztürk, R., Bakir, M., & Uzun, R. (2009). Efficacy of oral
ribavirin treatment in Crimean-Congo haemorrhagic fever: A quasi-experimental study from
Turkey. Journal of Infection, 58(3), 238–244. https://doi.org/10.1016/j.jinf.2009.01.014

398 [5] Swanepoel, R., Gill, D. E., Shepherd, A. J., Leman, P. A., Mynhardt, J. H., & Harvey, S.
399 (1989). The clinical pathology of Crimean-Congo hemorrhagic fever. *Reviews of infectious*400 *diseases*, *11 Suppl 4*, S794–S800. https://doi.org/10.1093/clinids/11.supplement_4.s794

401 [6] Ergonul O. (2008). Treatment of Crimean-Congo hemorrhagic fever. *Antiviral research*,
402 78(1), 125–131. <u>https://doi.org/10.1016/j.antiviral.2007.11.002</u>

403 [7] Almayahi, Z. K., Kindi, H. A., Jabri, I. H. S. H. A., Shaqsi, N. H. K. A., Hattali, N. A., 404 Hattali, A. A., Quyoodhi, B. A., & Dhuhli, K. A. (2022). Challenges in Diagnosis of Crimean-405 Congo Hemorrhagic Fever. Infectious Diseases in Clinical Practice, 30(2). https://doi.org/10.1097/ipc.00000000001108 406

- [8] Raabe V. N. (2020). Diagnostic Testing for Crimean-Congo Hemorrhagic Fever. *Journal of clinical microbiology*, *58*(4), e01580-19. https://doi.org/10.1128/JCM.01580-19
- 409 [9] Mayne, E. S., George, J. A., & Louw, S. (2023). Assessing Biomarkers in Viral Infection.
 410 Advances in experimental medicine and biology, 1412, 159–173. https://doi.org/10.1007/978-3411 031-28012-2_8
- 412 [10] Neogi, U., Elaldi, N., Appelberg, S., Ambikan, A. T., Kennedy, E. V., Dowall, S. D., Bagci,
- B., Gupta, S., Murillo, J. R., Akusjärvi, S. S., Monteil, V., Marko-Varga, G., Benfeitas, R.,
 Banerjea, A. C., Weber, F., Hewson, R., & Mirazimi, A. (2022). Multi-omics insights into hostviral response and pathogenesis in Crimean-Congo hemorrhagic fever viruses for novel
 therapeutic target. eLife, 11. https://doi.org/10.7554/elife.76071
- [11] Ak, Ç., Ergönül, Ö. & Gönen, M. A prospective prediction tool for understanding Crimean–
 Congo haemorrhagic fever dynamics in Turkey. Clin. Microbiol. Infect. 26, 123-e1 (2020).
- 419 [12] Nyamundanda, G., Gormley, I.C., Fan, Y. et al. MetSizeR: selecting the optimal sample size
- 420 for metabolomic studies using an analysis based approach. BMC Bioinformatics 14, 338 (2013).
- 421 https://doi.org/10.1186/1471-2105-14-338
- [13] Markley, J. L., Brüschweiler, R., Edison, A. S., Eghbalnia, H. R., Powers, R., Raftery, D., &
 Wishart, D. S. (2017). The future of NMR-based metabolomics. Current opinion in
 biotechnology, 43, 34–40. https://doi.org/10.1016/j.copbio.2016.08.001
- [14] Emwas, A. M. (2015). The Strengths and Weaknesses of NMR Spectroscopy and Mass
 Spectrometry with Particular Focus on Metabolomics Research. In Methods in molecular biology
 (pp. 161–193). Springer Science+Business Media. https://doi.org/10.1007/978-1-4939-23779_13
- [15] Munshi, S. U., Rewari, B. B., Bhavesh, N. S., & Jameel, S. (2013). Nuclear magnetic 429 resonance based profiling of biofluids reveals metabolic dysregulation in HIV-infected persons 430 431 and those anti-retroviral therapy. PloS one. 8(5), e64298. on https://doi.org/10.1371/journal.pone.0064298 432
- 433 [16] Shrinet, J., Shastri, J. S., Gaind, R., Bhavesh, N. S., & Sunil, S. (2016). Serum
 434 metabolomics analysis of patients with chikungunya and dengue mono/co-infections reveals
 435 distinct metabolite signatures in the three disease conditions. *Scientific reports*, *6*, 36833.
 436 https://doi.org/10.1038/srep36833
- [17] Wang, Z., Liang, H., Cao, H., Zhang, B., Li, J., Wang, W., Qin, S., Wang, Y., Xuan, L., Lai,
 L., & Shui, W. (2019). Efficient ligand discovery from natural herbs by integrating virtual
 screening, affinity mass spectrometry and targeted metabolomics. Analyst, 144(9), 2881–2890.
 https://doi.org/10.1039/c8an02482k
- 441 [18] Karakus, N., Duygu, F., Rustemoglu, A., & Yigit, S. (2022). Methylene-tetrahydrofolate 442 reductase gene C677T and A1298C polymorphisms as a risk factor for Crimean-Congo 443 hemorrhagic fever. Nucleosides, Nucleotides Nucleic Acids, 41(9), 878-890. & 444 https://doi.org/10.1080/15257770.2022.2085296

[19] Byszewska, M., Śmietański, M., Purta, E., & Bujnicki, J. M. (2014). RNA
methyltransferases involved in 5' cap biosynthesis. RNA Biology, 11(12), 1597–1607.
https://doi.org/10.1080/15476286.2015.1004955

[20] Brecher, M., Chen, H. S., Liu, B., Banavali, N. K., Jones, S., Zhang, J., Li, Z., Kramer, L.
D., & Li, H. (2015b). Novel Broad Spectrum Inhibitors Targeting the Flavivirus
Methyltransferase. PLOS ONE, 10(6), e0130062. https://doi.org/10.1371/journal.pone.0130062

[21] Valle, C., Martin, B., Ferron, F., Roig-Zamboni, V., Desmyter, A., Debart, F., Canard, B.,
Coutard, B., & Decroly, E. (2021). First insights into the structural features of Ebola virus
methyltransferase activities. *Nucleic Acids Research*, 49(3), 1737–1748.
https://doi.org/10.1093/nar/gkaa1276

[22] Tchesnokov, E. P., Bailey-Elkin, B. A., Mark, B. L., & Götte, M. (2020). Independent
inhibition of the polymerase and deubiquitinase activities of the Crimean-Congo Hemorrhagic
Fever Virus full-length L-protein. PLOS Neglected Tropical Diseases, 14(6), e0008283.
https://doi.org/10.1371/journal.pntd.0008283

459 [23] Robins, R. K., Revankar, G. R., McKernan, P. A., Murray, B. K., Kirsi, J. J., & North, J. A. 460 (1985). The importance of IMP dehydrogenase inhibition in the broad spectrum antiviral activity 461 Advances of ribavirin and selenazofurin. in Enzyme Regulation. 24, 29-43. https://doi.org/10.1016/0065-2571(85)90068-8 462

[24] Rothan, H. A., Abdulrahman, A. Y., Khazali, A. S., Rashid, N. N., Chong, T. T., & Yusof,
R. (2019). Carnosine exhibits significant antiviral activity against Dengue and Zika virus.
Journal of Peptide Science, 25(8). https://doi.org/10.1002/psc.3196

[25] Saadah, L. M., Deiab, G. I. A., Al-Balas, Q., & Basheti, I. A. (2020). Carnosine to Combat
Novel Coronavirus (nCoV): Molecular Docking and Modeling to Cocrystallized Host
Angiotensin-Converting Enzyme 2 (ACE2) and Viral Spike Protein. Molecules, 25(23), 5605.
https://doi.org/10.3390/molecules25235605

470 [26] Chon, J., Stover, P. J., & Field, M. S. (2017). Targeting nuclear thymidylate biosynthesis.
471 Molecular Aspects of Medicine, 53, 48–56. https://doi.org/10.1016/j.mam.2016.11.005

472 [27] De Clercq E. (2005). Potential clinical applications of the CXCR4 antagonist bicyclam
473 AMD3100. Mini reviews in medicinal chemistry, 5(9), 805–824.
474 https://doi.org/10.2174/1389557054867075

475 [28] Yen, Y. C., Kong, L. X., Lee, L., Zhang, Y. Q., Li, F., Cai, B. J., & Gao, S. Y. (1985).
476 Characteristics of Crimean-Congo hemorrhagic fever virus (Xinjiang strain) in China. The
477 American journal of tropical medicine and hygiene, 34(6), 1179–1182

478 [29] National Center for Biotechnology Information (2023). PubChem Compound Summary for

479 CID 444266, Maleic Acid. Retrieved August 15, 2023 from

480 https://pubchem.ncbi.nlm.nih.gov/compound/Maleic-Acid

- 481 [30] Bergeron, M. G., Mayers, P., & Brown, D. T. (1996). Specific effect of maleate on an apical
- 482 membrane glycoprotein (gp330) in proximal tubule of rat kidneys. American Journal of
- 483 *Physiology-renal Physiology*, 271(4), F908–F916.
- 484 <u>https://doi.org/10.1152/ajprenal.1996.271.4.f908</u>

485



Figure 1 PLS-DA analysis of patient samples with severe and moderate infection level for four
consecutive days with the control group (S: severe, M: moderate, C: Control) a. Matching score
plots for the first five components of the PLS-DA analysis of all samples. b. partial Least
Squares Discriminant Analysis score plot. c. Variable importance score plot in PLS-DA VIP
Projection. d. corresponding compounds in detected increases on the spectra. Component 1:
accuracy=0.817, (R2=0.246, Q2=0.142), component 2: accuracy=0.833, (R2=0.394, Q2=0.210),

493 component 3: accuracy=0.809, (R2=0.545, Q2=0.225), component 4: accuracy=0.777, 494 (R2=0.644, Q2=0.250), component 5: accuracy=0.769, (R2=0.782, Q2=0.205)

495



496

497

Figure 2 PLS-DA analysis of patient samples with severe and moderate infection level for first two days with the control group matching score plots for the first five components of the PLS-DA analysis of samples from day 1 and day 2 as labeled mild (M), severe (S) and compared with the control group (C). b, partial Least Squares Discriminant Analysis score plot. c, Variable importance score plot in PLS-DA VIP Projection. d, corresponding compounds in detected increases on the spectra. Component 1: accuracy=0.0837, (R2=0.585, Q2=0.417), component 2: accuracy=0.821, (R2=0.627, Q2=0.433), component 3: accuracy=0.793, (R2=0.804, Q2=0.352) 505



506

Figure 3 PLS-DA analysis of patient samples with moderate infection level for first two days 507 with the control group and PLS-DA analysis of patient samples with severe infection level for 508 509 first two days with the control group (S:severe, M: moderate, C:Control) a, partial Least Squares Discriminant Analysis score plot. Component 1: accuracy=0.983, (R2=0.821, Q2=0.739), 510 511 accuracy=0.983, (R2=0.860, O2=0.790), component 3: accuracy=0.983, component 2: (R2=0.954, Q2=0.829) b, Variable importance score plot in PLS-DA VIP Projection. c, partial 512 513 Least Squares Discriminant Analysis score plot. Component 1: accuracy=0.950, (R2=0.857, Q2=0.702), component 2: accuracy=1, (R2=0,938, Q2=0.797), component 3: accuracy=1, 514 515 (R2=0.982, Q2=0.824) d, Variable importance score plot in PLS-DA VIP Projection. e, corresponding compounds in detected increases on the spectra. f, corresponding compounds in 516 detected increases on the spectra. 517



519

520

JZU



521

Figure 4 Main metabolic pathways of metabolites detected by metabolomics approach a. S Adenosyl-L-homocysteine and nearest neighbor in Cysteine and methionine metabolism b. GTP

and nearest neighbor in Purine metabolism c. Carnosine and nearest neighbor in Histidine
 metabolism d. Deoxyuridine and nearest neighbor in Pyrimidine metabolism